Drug intelligence / Profile preview

bupropion + remogliflozin etabonate

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Bupropion + GSK189075 is a drug combination consisting of the norepinephrine-dopamine reuptake inhibitor (NDRI) bupropion and the sodium-glucose cotransporter 2 (SGLT2) inhibitor remogliflozin etabonate (formerly GSK189075). Developed by GlaxoSmithKline, this combination was evaluated in Phase I clinical trials (such as NCT00625859) to assess the safety, tolerability, and pharmacokinetic interactions of the two agents when co-administered. Bupropion is traditionally used for major depressive disorder and smoking cessation, while remogliflozin etabonate is a prodrug investigated for the treatment of type 2 diabetes mellitus and non-alcoholic steatohepatitis (NASH).

Brand names: Wellbutrin SR
Other names: bupropion + GSK189075remogliflozin etabonate + bupropion

Targets

DAT (Dopamine plasma membrane transport protein)Nicotinic Acetylcholine ReceptorNET (Norepinephrine Transporter)

Beyond the preview

Go deeper on bupropion + remogliflozin etabonate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupropion + remogliflozin etabonate.

Explore the full profile